Overview
Dr. Driscoll participates in:
-multi-institutional studies for the treatment of high risk neuroblastoma patients using high dose chemotherapy with stem cell transplant and the development of new therapies for high risk neuroblastoma patients.
-Cellular therapies, including Tisagenlecleucel for CD19(+) B-cell ALL and gene therapy for patients with Sickle Cell Disease.
-multi-institutional studies for the treatment of high risk neuroblastoma patients using high dose chemotherapy with stem cell transplant and the development of new therapies for high risk neuroblastoma patients.
-Cellular therapies, including Tisagenlecleucel for CD19(+) B-cell ALL and gene therapy for patients with Sickle Cell Disease.
Current Appointments & Affiliations
Associate Professor of Pediatrics
·
2024 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Recent Publications
Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.
Journal Article Bone Marrow Transplant · December 10, 2025 Full text Link to item CiteReal-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
Journal Article Blood Adv · October 28, 2025 Since the first approval of tisagenlecleucel in 2017, pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) may receive this CD19-directed chimeric antigen receptor T-cell therapy. We report real-world data ... Full text Link to item CiteNewborn Screening for Hurler Syndrome Facilitates Early Transplant and Good Outcomes.
Journal Article Pediatr Neurol · February 2025 BACKGROUND: Hematopoietic cell transplantation (HCT) is the standard of care treatment for children with Hurler syndrome (HS). This study describes the impact of newborn screening (NBS) on HCT outcomes for these patients. METHODS: Retrospective study of HS ... Full text Link to item CiteRecent Grants
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Subjects
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2020 - 2024A multicenter study of apheresis collection of peripheral blood mononuclear (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2020Acid Sphingomyelinase Activation in Apoptosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2002View All Grants
Education, Training & Certifications
Ohio State University ·
1990
M.D.